Phthalic Acid

Phthalic Acid

SCHEMBL106332

O=C([O-])c1ccccc1C(=O)[O-].[Li+].[Li+]

nearest known ligand 0.64

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

GSK3AGSK3BIMPA1

The experimentally established mechanism targets of Phthalic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.64
KDM4E B2RXH2 4/20 0.64
HPGD P15428 3/20 0.64
CA2 P00918 2/20 0.50
CA4 P22748 2/20 0.50
ALOX15 P16050 2/20 0.50
NFKB1 P19838 1/20 0.43
MAPK1 P28482 1/20 0.43
CYP2C19 P33261 1/20 0.43
BLM P54132 1/20 0.43
CES2 O00748 3/20 0.42
CES1 P23141 3/20 0.42
CA12 O43570 1/20 0.42
CA1 P00915 1/20 0.42
HMGB1 P09429 1/20 0.42
CA6 P23280 1/20 0.42
CA7 P43166 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
CA9 Q16790 1/20 0.42
NAPRT Q6XQN6 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Phthalic Acid SCHEMBL2378712 0.97 ALDH1A1 (0.61) ALDH1A1KDM4EHPGDCA2CA4
Phthalic Acid SCHEMBL2291422 0.94 ALDH1A1 (0.64) ALDH1A1KDM4EHPGDCA2CA4
Phthalic Acid SCHEMBL5667381 0.94 ALDH1A1 (0.64) ALDH1A1KDM4EHPGDCA2CA4
Phthalic Acid SCHEMBL11470622 0.94 ALDH1A1 (0.64) ALDH1A1KDM4EHPGDCA2CA4
Phthalic Acid SCHEMBL7199331 0.94 ALDH1A1 (0.64) ALDH1A1KDM4EHPGDCA2CA4
Phthalic Acid SCHEMBL10706022 0.94 ALDH1A1 (0.64) ALDH1A1KDM4EHPGDCA2CA4
Phthalic Acid SCHEMBL3942385 0.94 ALDH1A1 (0.64) ALDH1A1KDM4EHPGDCA2CA4
Phthalic Acid SCHEMBL16341729 0.94 ALDH1A1 (0.64) ALDH1A1KDM4EHPGDCA2CA4
Phthalic Acid SCHEMBL4351997 0.94 ALDH1A1 (0.64) ALDH1A1KDM4EHPGDCA2CA4
Phthalic Acid SCHEMBL128144 0.94 ALDH1A1 (0.64) ALDH1A1KDM4EHPGDCA2CA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 261 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3825278-B1 METHOD FOR PREPARING HIGH-PURITY BISFLUOROSULFONYLIMIDE SALT SHANGHAI ROLECHEM CO LTD (CN) 2025-12-17 EP claimed
CN-119786761-A Static halogen battery based on multiple electron transfer mechanism 郑州大学 2025-04-08 CN claimed
CN-119280450-A Medical fabric dressing with long-acting disinfection and sterilization functions and preparation method thereof 孙国明 2025-01-10 CN claimed
CN-118844836-A Long-acting disinfection and sterilization wet (towel) paper 孙国明 2024-10-29 CN claimed
CN-118844448-A Preparation method of long-acting antibacterial liquid 孙国明 2024-10-29 CN claimed
CN-116544535-A Lithium supplementing additive, positive electrode slurry and positive electrode of non-negative electrode lithium metal battery 哈尔滨工业大学 2023-08-04 CN claimed
CN-113745459-A Positive electrode slurry and preparation method and application thereof 远景动力技术(江苏)有限公司 2021-12-03 CN claimed
EP-3825278-A1 METHOD FOR PREPARING HIGH-PURITY BISFLUOROSULFONYLIMIDE SALT Shanghai Rolechem Co., Ltd. (CN) 2021-05-26 EP claimed
CN-109183004-B Method for improving stability of battery by adopting circulating winding type atomic layer deposition equipment 华中科技大学 2020-02-14 CN claimed
CN-106356514-B Lithium battery anode, lithium battery and preparation method thereof 惠州亿纬锂能股份有限公司 2020-01-03 CN claimed
US-10243236-B2 Overcharging preventive electrolyte and lithium-ion battery CONTEMPORARY AMPEREX TECHNOLOGY CO., LIMITED (CN) 2019-03-26 US claimed
EP-2621012-B1 MANUFACTURING METHOD FOR ELECTROLYTE, ELECTROLYTE SOLUTION, GEL ELECTROLYTE, ELECTROLYTE MEMBRANE AND GEL ELECTROLYTE BATTERY, AND LITHIUM-ION SECONDARY BATTERY SEKISUI CHEMICAL CO LTD (JP) 2018-01-10 EP claimed
US-20170018803-A1 OVERCHARGING PREVENTIVE ELECTROLYTE AND LITHIUM-ION BATTERY CONTEMPORARY AMPEREX TECHNOLOGY (HONG KONG) LIMITED (CN) 2017-01-19 US claimed
CN-115458808-B Method for producing lithium fluorosulfonate, nonaqueous electrolyte solution, and nonaqueous electrolyte secondary battery 三菱化学株式会社 2026-05-15 CN disclosed
US-20260118767-A1 REVERSE PATTERNING PROCESS SHIN-ETSU CHEMICAL CO., LTD. (JP) 2026-04-30 US disclosed
US-20260044081-A1 COMPOSITION FOR FORMING SILICON-CONTAINING RESIST FILM AND PATTERNING PROCESS SHIN-ETSU CHEMICAL CO., LTD. (JP) 2026-02-12 US disclosed
EP-0296250-A1 POLYARYLENE SULFIDE AND PROCESS FOR ITS PRODUCTION IDEMITSU PETROCHEMICAL COMPANY LIMITED (JP) 1988-12-28 EP disclosed
EP-0268765-A2 Resin comprising a polyphenylene sulfide/polyphenylene sulfone block copolymer, process for preparing the copolymer and molded article DAINIPPON INK AND CHEMICALS, INC. (JP) 1988-06-01 EP disclosed
US-4490522-A REACTING POLYHALOGENATED AROMATIC COMPOUND WITH ALKALI METAL SULFIDE IN PRESENCE OF OXYALKYLENE COMPOUND DAINIPPON INK & CHEMICALS, INC. (JP) 1984-12-25 US disclosed
US-3943164-A IMPROVE DYEABILITY OF OLEFIN POLYMERS PHILLIPS PETROLEUM COMPANY (US) 1976-03-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260118767-A1 REVERSE PATTERNING PROCESS EFNA1, EPHA4, ETV6 ALDH1A1 4452/4885KDM4E 588/4885HPGD 4878/4885
US-20260044081-A1 COMPOSITION FOR FORMING SILICON-CONTAINING RESIST FILM AND PATTERNING PROCESS SMC1A, SPOUT1, LBR ALDH1A1 1558/4885KDM4E 2013/4885HPGD 4586/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.